Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GDLEP
ADC Name
CD19 mAb-TP
Synonyms
CD19 mAb-TP
   Click to Show/Hide
Organization
Chinese Academy of Medical Sciences; Peking Union Medical College; Central South University.
Drug Status
Investigative
Drug-to-Antibody Ratio
4.75
Structure
Antibody Name
undisclosed
Antigen Name
B-lymphocyte antigen CD19 (CD19)
  Antigen Info 
Payload Name
Triptolide
  Payload Info 
Therapeutic Target
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
  Target Info 
Linker Name
PEG2000-NHS
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
6.13
nM
CVCL_0213
Normal
Half Maximal inhibitory Concentration (lC50) 
27.21
uM
CVCL_0213
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 6.13 nM Positive CD19 expression (CD19+++/++)
Method Description
Cells were treated with corresponding agents with various concentrations for 12 or 48 h, and cell viability was detected by MTT (C0009M, Beyotime) assay. Dose-response curves were fitted by GraphPad Prism 9 software. Then, IC50 values were calculated.
In Vitro Model Normal CHO cells (CD19+) CVCL_0213
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 27.21 uM Negative CD19 expression (CD19-)
Method Description
Cells were treated with corresponding agents with various concentrations for 12 or 48 h, and cell viability was detected by MTT (C0009M, Beyotime) assay. Dose-response curves were fitted by GraphPad Prism 9 software. Then, IC50 values were calculated.
In Vitro Model Normal CHO cells (CD19-) CVCL_0213
References
Ref 1 A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus